1. Home >
  2. Curi Bio Acquires Cartox

M&A Deal Summary

Curi Bio Acquires Cartox

On March 29, 2022, Curi Bio acquired medical products company Cartox from StemBioSys

Acquisition Highlights
  • This is Curi Bio’s 1st transaction in the Medical Products sector.
  • This is Curi Bio’s 2nd transaction in the United States.
  • This is Curi Bio’s 1st transaction in Michigan.

M&A Deal Summary
Date 2022-03-29
Target Cartox
Sector Medical Products
Buyer(s) Curi Bio
Sellers(s) StemBioSys
Deal Type Divestiture

Target

Cartox

Flint, Michigan, United States
Cartox is a private company that develops innovative assays for human cardiotoxicity high throughput screening. Its patent-pending technologies utilize human stem cell-derived cardiomyocytes for detecting potential cardiotoxicity associated with medications, oncology drugs, environmental toxins, and genetics. Cartox is based in Flint, Michigan.

Search 204,717 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Curi Bio

Seattle, Washington, United States
Category Company
Sector Technology Hardware
DESCRIPTION

Curi Bio develops and commercializes integrated drug discovery platforms leveraging human iPSC-derived cells, tissue-specific biosystems, and AI/ML-enabled phenotypic screening. Curi Bio is based in Seattle, Washington.

DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
State (Michigan) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-07-23 Dana Solutions

Palo Alto, California, United States

Dana Solutions LLC is a developer of an application of artificial intelligence and machine learning to in vitro cell-based assays. Dana Solutions is based in Palo Alto, California.

Buy -

Seller(S) 1

SELLER

StemBioSys

San Antonio, Texas, United States
Category Company
Founded 2010
Sector Life Science
DESCRIPTION

StemBioSys is a privately-held biomedical company with its technologies representing the next evolution in cell research and is branded to the research market under the CELLvo label. The centerpiece of these technologies is its CELLvo Matrix. This cell-derived microenvironment allows a variety of cells to replicate (multiply in number) more rapidly and express markers indicative of potency beyond that seen with traditional tissue culture substrates. The company also has several cell products isolated and expanded on our matrix. It has also developed a novel approach for preclinical cardiac safety testing, which is currently being used by several commercial partners. StemBioSys was formed in 2010 and is based in San Antonio, Texas.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
State (Michigan) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-08 Cartox

Flint, Michigan, United States

Cartox is a private company that develops innovative assays for human cardiotoxicity high throughput screening. Its patent-pending technologies utilize human stem cell-derived cardiomyocytes for detecting potential cardiotoxicity associated with medications, oncology drugs, environmental toxins, and genetics. Cartox is based in Flint, Michigan.

Buy -
Mergr

Product

Company

Legal